Sign up to save your podcasts
Or
Share Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'
Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.
View all episodes
By BiotechTV
5
44 ratings
Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.
More shows like BiotechTV - News
View all
Planet Money
30,626 Listeners
Odd Lots
1,863 Listeners
a16z Podcast
1,085 Listeners
The Readout Loud
325 Listeners
The Journal.
6,059 Listeners
Biotech 2050 Podcast
60 Listeners
All-In with Chamath, Jason, Sacks Friedberg
9,840 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
ACQ2 by Acquired
260 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
497 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners